Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

European Innovation Council · Running

CLUSTREL Seizure Cluster Relief through Smart Therapeutic Management

Coordinator
Consorzio Interuniversitario Nazionale per La Scienza E Tecnologia Dei Materiali, Italy
Runs
1 June 2026 to 31 May 2029
Status
Running
EU funding
€2.5m
Total cost
—
Partners
4 organisations in 2 countries
Type
European Innovation Council
Grant agreement
101287957

What the project is doing

In the project's own words, from its summary on CORDIS.

Epileptic seizures significantly impair patients' quality of life and autonomy. Despite recent advancements in wearable monitoring of brain activity, patients still struggle with seizures management and their pharmacological mitigation. CLUSTREL addresses this problem. It will develop a smart, non-invasive oral device for on-demand delivery of rescue medication to treat epileptic seizure clusters, a critical unmet need of ~15 million patients with drug-resistant epilepsy worldwide.

The technology uses a patented, graphene-based system that releases medication within minutes of seizure onset, triggered manually or automatically by an existing external EEG sensor. The project's objective is to advance this technology from a lab-validated proof-of-concept (TRL 4) to a clinically relevant prototype demonstrated in a relevant environment (TRL 6). This will be achieved by:- Optimizing the graphene-drug pharmaceutical formulation for stability and rapid mucosal absorption;- Engineering a miniaturized, biocompatible, and user-friendly prototype for use in animal models;- Conducting comprehensive preclinical validation of the device's safety and efficacy in vitro, in rodent models of epilepsy, and in large animal models;- Establishing a spin-off company to manage IP, define the regulatory pathway, and secure strategic partnerships for commercialization.

CLUSTREL aligns perfectly with EIC's TRANSITION vision, as it addresses a significant healthcare challenge by translating a breakthrough European technology into a market-ready medical device. It promises to reduce hospitalizations, lower healthcare costs, and significantly improve patient autonomy and quality of life, strengthening Europe's leadership in MedTech innovation.

Who is involved

OrganisationCityCountryRole
Consorzio Interuniversitario Nazionale per La Scienza E Tecnologia Dei MaterialiFirenzeItalyCoordinator
Future Needs Management Consulting LtdNicosiaCyprusParticipant
Sindrel Medtech S.r.l.TriesteItalyThird party
Universita Degli Studi Di Modena E Reggio EmiliaModenaItalyThird party

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI